First test of the new drug 4A10 in hard-to-treat acute lymphoblastic leukemia or lymphoma
Tests 4A10, a new drug, in adults with relapsed lymphoblastic leukemia or lymphoma.
Key facts
- Who runs it
- Allterum Therapeutics, Inc
- Where
- Aurora, Cincinnati, Fort Worth, Houston, Indianapolis, New York, and Philadelphia, United StatesSee the 7 sites
- Trial code
- Registry title
- First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 24 people, planned
- Started
- 1 Jun 2026
- Expected to end
- Sept 2028
- Type of study
- Interventional
- Treatments tested
- 4A10
- Record updated
- 1 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma that came back or did not respond to treatment, and has no treatment meant to remove all of the disease.
- Age
- 18 years or older
- Sex
- Men and women can both join
- Disease stage
- T-cell or B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that came back or did not respond, with no treatment meant to remove all of the disease
- Earlier treatment
- Must not have had earlier treatment aimed at CD127 (anti-CD127 therapy)
Main reasons for not taking part
- Cancer spread to the central nervous system (CNS3 disease)
- DNA fragility syndromes such as Fanconi or Bloom
- Down syndrome (trisomy 21)
- Earlier anti-CD127 treatment
- Infections that are not under control
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Confirmed diagnosis of T/B-ALL or T/B-LL
- Relapsed or refractory disease without curative options
- Adequate organ function and performance status
Who cannot take part
- Prior exposure to anti-CD127 therapies
- Patients with CNS3 disease
- Patients with DNA fragility syndromes (e.g., Fanconi, Bloom), trisomy 21 (Down Syndrome)
- Uncontrolled infections
Where in United States
- Children's Hospital ColoradoAurora, United StatesContact: Kelly Faulk, MDTaking people
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Lori BackusNot yet recruiting
- Cook Children's Medical CenterFort Worth, United StatesContact: Heather JerniganTaking people
- Texas Children's HospitalHouston, United StatesContact: Eric Schafer, MDTaking people
- Riley Children's HosptialIndianapolis, United StatesContact: Sara QuentantTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Maria Luisa Sulis, MD (principal investigator)Taking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Susan Rheingold, MDNot yet recruiting
About the trial
What the trial wants to find out
ALT-101 is a first-in-human Phase 1 clinical trial testing a new antibody drug called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.
Read full original descriptionShow less
4A10 is a targeted therapy designed to recognize and attach to a specific protein (CD127) found on leukemia cells. Once it binds, it works in two ways: it blocks growth signals that help cancer cells survive, and it helps the immune system find and destroy those cancer cells.
In this study, patients receive 4A10 through an intravenous (IV) infusion once a week. The main goal of the trial is to find out if the drug is safe, what dose can be given, and how the body processes it. Researchers will also look for early signs that the treatment may be working.
The study starts with small groups of patients receiving increasing doses to carefully monitor safety. Each patient is closely observed during the first treatment cycle (about 4-6 weeks) to watch for side effects. If the treatment is helping and is well tolerated, patients may continue treatment for up to six cycles.
Overall, this study is an early step in testing a new, targeted immune-based therapy for difficult-to-treat blood cancers.
The group in the trial
- Single ArmTreatment being tested
Participants receive 4A10 administered by intravenous route according to the protocol-defined dosing schedule in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or discontinuation per investigator decision.
Treatment: 4A10
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A First in Human, Phase 1, Open-Label Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 4A10 Monotherapy In Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Plain-language title
- First test of the new drug 4A10 in hard-to-treat acute lymphoblastic leukemia or lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 1 September 2026